Skip to content
Peptigraph home
Shop Peptides50% off*

Orforglipron for Diabetes: What the Evidence Shows

What human and animal studies show about Orforglipron for diabetes, how strong that evidence is, and what is still unproven.

Medical review pendingOral small-molecule GLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
6
with an outcome for diabetes, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for diabetes, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
6
with an outcome for diabetes

Evidence for diabetes

Each row is an outcome related to diabetes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Orforglipron for diabetes: outcomes in published studies
OutcomeResultStudy typeSource
Body weight changeIn people with diabetes, bodyweight changed by -5·1% (6 mg), -7·0% (12 mg) and -9·6% (36 mg) with orforglipron vs -2·5% with placebo at week 72.Human RCTn = 1613Lancet 2026, PMID 41275875
Glycaemic control vs oral semaglutideGlycated hemoglobin changed by -1·71% (orforglipron 12 mg) and -1·91% (36 mg) vs -1·23% (semaglutide 7 mg) and -1·47% (14 mg) at week 52.Human controlled trialn = 1698Lancet 2026, PMID 41765029
Glycaemic control vs dapagliflozinGlycated hemoglobin fell by 1·23%, 1·50% and 1·56% (orforglipron 3, 12, 36 mg) vs 0·81% with dapagliflozin 10 mg.Human controlled trialn = 962Lancet 2026, PMID 42259339
Glycated hemoglobin changeGlycated hemoglobin fell by 1.24, 1.47 and 1.48 percentage points (3, 12, 36 mg) vs 0.41 with placebo at week 40.Human RCTn = 559The New England journal of medicine 2025, PMID 40544435
Body weightBody weight changed by -4.5%, -5.8% and -7.6% (3, 12, 36 mg) vs -1.7% with placebo.Human RCTn = 559The New England journal of medicine 2025, PMID 40544435
Glycaemic control and body weightGlycated hemoglobin fell by up to 2·10% with orforglipron vs 0·43% with placebo and 1·10% with dulaglutide at week 26.Human RCTn = 383Lancet 2023, PMID 37369232
Glycated hemoglobin and weightGlycated hemoglobin changed by -1.5% to -1.8% with orforglipron vs -0.4% with placebo; body weight changed by -0.24 to -5.8 kg vs 0.5 kg.Human RCTn = 68Diabetes, obesity & metabolism 2023, PMID 37264711

Orforglipron and diabetes are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Lancet 2026, PMID 41275875

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Diabetes in plain terms

MedlinePlus explains that insulin is a hormone made by the pancreas.[7]

Type 2 diabetes trials

In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks.[4]

Against oral semaglutide at week 52, HbA1c fell 1.71% with orforglipron 12 mg and 1.91% with 36 mg, versus 1.23% with semaglutide 7 mg and 1.47% with 14 mg.[2]

Against dapagliflozin, every orforglipron dose was non-inferior in reducing HbA1c at week 40.[3]

In adults with type 2 diabetes, 1613 were randomly assigned after dose escalation to orforglipron 6 mg (n=329), 12 mg (n=332), 36 mg (n=322) or placebo (n=630).[1]

Registered HbA1c measures

The phase 2 record NCT05048719 registered change from baseline in HbA1c compared with placebo.[8]

The ATTAIN-2 record NCT05872620 registered change from baseline in hemoglobin A1c.[9]

Other peptides people research for diabetes

SemaglutideTirzepatideRetatrutideTesamorelinMOTS-cSurvodutideCagriSemaMazdutide
All peptides for diabetes, compared

Common questions

Does Orforglipron help with diabetes?

The strongest study we summarise for diabetes is human rct evidence, across 6 studies with an outcome for diabetes. A trial result is not an approval; see the legal status.

Is Orforglipron approved for diabetes?

Orforglipron is FDA approved (Foundayo, Apr 2026). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for diabetes?

There is no single answer. Our diabetes overview compares each candidate by evidence grade and legal status rather than by popularity.

Is orforglipron approved for type 2 diabetes?

The Foundayo label cited here approves it for weight management; the diabetes results come from trials.[10]

More on Orforglipron

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  2. 2Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
  3. 3Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
  4. 4Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
  5. 5Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
  6. 6Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
  7. 7Official web pageOfficial web page · web page
  8. 8A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  9. 9A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  10. 10FOUNDAYO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.